New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
10:23 EDTFAST, JNJ, EPB, FDOOptions with decreasing implied volatility: FDO JNJ FAST EPB
News For FDO;JNJ;FAST;EPB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 21, 2014
07:43 EDTFDODollar Tree price target raised to $74 from $68 at UBS
Subscribe for More Information
November 20, 2014
13:04 EDTEPBKinder Morgan announces shareholder approval of merger transactions
Kinder Morgan (KMI) announced that at special meetings held by each of KMI, Kinder Morgan Energy Partners (KMP), Kinder Morgan Management (KMR) and El Paso Pipeline Partners (EPB), unitholders and shareholders approved all proposals related to the merger transactions previously announced on Aug. 10. More than 95% of the votes cast at the special meeting of each company were voted in favor of the proposals related to the merger transactions. The deadline for KMP and EPB unitholders to elect the form of consideration they wish to receive in each of KMP’s and EPB’s pending mergers with KMI is 5:00 p.m. ET on Nov. 24, 2014. The election deadline may be extended, in which case KMI will issue a press release announcing the new election deadline. The closing of each merger is expected to occur on Nov. 26, 2014. Accordingly, it is expected that Nov. 26 will be the last trading day for KMP and EPB units as well as KMR shares.
09:43 EDTEPBKinder Morgan to host special shareholder meeting
Subscribe for More Information
09:37 EDTEPBEl Paso Pipeline to host special shareholder meeting
Special shareholder meeting to approve the merger agreement with Kinder Morgan, Inc. is being held in Houston, Texas on November 20 at 11 am.
09:30 EDTFDODollar Tree says working to close Family Dollar deal 'as soon as possible'
Subscribe for More Information
November 19, 2014
15:15 EDTFDODollar General affirms commitment to Family Dollar deal, says FTC review ongoing
Subscribe for More Information
15:14 EDTFDODollar General says actively engaged in ongoing FTC review process for deal
Subscribe for More Information
15:13 EDTFDODollar General affirms commitment to Family Dollar acquisition
09:04 EDTJNJJohnson & Johnson submits NDA for three-month paliperidone palmitate
Janssen Research & Development, a Johnson & Johnson company, announced the submission of a New Drug Application, or NDA, for three-month atypical antipsychotic paliperidone palmitate to the FDA. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. If approved, it will be the first and only long-acting atypical antipsychotic that has a four times a year dosing schedule.
08:31 EDTFDOFamily Dollar reschedules special meeting of shareholders to December 23
Subscribe for More Information
06:39 EDTFDODollar General may have to sell over 4K stores for deal approval, NY Post says
The Federal Trade Commission may require Dollar General (DG) to sell more than 4,000 of its stores to gain approval of its deal to buy Family Dollar (FDO), according to The New York Post. Dollar General had previously said that it was willing to sell 1,500 of its stores to facilitate the deal, the newspaper stated. Reference Link
06:30 EDTJNJJohnson & Johnson, Boston Scientific trial set to start tomorrow, Reuters says
Subscribe for More Information
November 17, 2014
07:16 EDTJNJMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 14, 2014
17:27 EDTFDOPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
16:21 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
14:53 EDTJNJCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
07:05 EDTEPBKinder Morgan says expected closing date of merger Nov. 24
Subscribe for More Information
November 13, 2014
16:28 EDTJNJGeron announces global strategic collaboration with Janssen Biotech
Geron (GERN) announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company, to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis, or MF, and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome, or MDS, and acute myelogenous leukemia, or AML. Under the terms of the agreement, Geron will receive an initial payment of $35M due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900M for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen.
11:54 EDTJNJJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
10:44 EDTJNJMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use